Valuation: Pulmatrix Inc

Market Cap 5.69M 5.02M 4.75M 4.31M 8.07M 546M 8.15M 56.96M 21.95M 279M 21.35M 20.89M 897M P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 1.6M 1.41M 1.33M 1.21M 2.27M 153M 2.29M 16.01M 6.17M 78.33M 6M 5.87M 252M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.22%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 2024-07-19
Director TitleAgeSince
Director/Board Member 58 2019-10-31
Director/Board Member 57 2020-06-22
Director/Board Member 55 2020-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-8.33%+504.03% - - 5.69M
-0.70%-4.28%+52.62%+86.42% 71.53B
-0.02%+1.48%+37.43%+81.63% 60.12B
+4.77%+6.16%+36.77%+26.10% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.51%-2.28%+0.48%-9.27% 24.76B
+0.69%+1.79%+21.04%-4.54% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+2.96%+0.83%-5.25%+519.59% 14.41B
Average +0.11%-0.79%+36.46%+173.79% 30.57B
Weighted average by Cap. +0.52%-1.52%+36.62%+129.83%

Financials

2024 2025
Net sales 7.81M 6.89M 6.52M 5.91M 11.08M 749M 11.19M 78.19M 30.14M 382M 29.31M 28.67M 1.23B -
Net income -9.56M -8.44M -7.98M -7.24M -13.57M -917M -13.7M -95.75M -36.9M -468M -35.89M -35.11M -1.51B -5.16M -4.56M -4.31M -3.91M -7.33M -495M -7.4M -51.71M -19.93M -253M -19.38M -18.96M -814M
Net Debt -9.52M -8.4M -7.95M -7.21M -13.52M -914M -13.65M -95.37M -36.76M -467M -35.75M -34.97M -1.5B -4.09M -3.61M -3.41M -3.1M -5.8M -392M -5.86M -40.95M -15.78M -200M -15.35M -15.02M -645M
Logo Pulmatrix Inc
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
-